Centro de Investigación Médica Aplicada-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2018

  1. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

    Nature Communications, Vol. 9, Núm. 1